FDA Determines Regulatory Review Period for BETAXON Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for BETAXON, a human drug product, in accordance with patent extension regulations, as part of a formal application submitted to the US Department of Commerce.